Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Capital Expenditures (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Capital Expenditures for 4 consecutive years, with $11000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures changed N/A to $11000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $279000.0 through Dec 2025, up 720.59% year-over-year, with the annual reading at $371000.0 for FY2025, 991.18% up from the prior year.
  • Capital Expenditures for Q4 2025 was $11000.0 at Centessa Pharmaceuticals, down from $234000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $652000.0 in Q4 2022, with the low at $10000.0 in Q2 2023.
  • Average Capital Expenditures over 4 years is $144090.9, with a median of $43000.0 recorded in 2023.
  • The sharpest move saw Capital Expenditures tumbled 95.71% in 2023, then surged 588.24% in 2025.
  • Over 4 years, Capital Expenditures stood at $652000.0 in 2022, then crashed by 95.71% to $28000.0 in 2023, then grew by 21.43% to $34000.0 in 2024, then tumbled by 67.65% to $11000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $11000.0, $234000.0, and $34000.0 for Q4 2025, Q3 2025, and Q3 2024 respectively.